Search

everythinglearnresearchcommunity

for

Search:↓

Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

Metformin and rosiglitazone improve blood vessel function in women with PCOS, with metformin also reducing insulin resistance and testosterone levels.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Stopping gefitinib improved scalp condition in a woman with lung cancer.

DN106212, an extract from a plant, is better at promoting hair growth than other tested substances by affecting hair growth factors and follicle development.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

Glycyrrhizin nanocarriers effectively deliver baicalin to hair follicles, promoting hair growth and offering a promising alopecia treatment with fewer side effects.

JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.

The treatment temporarily improved symptoms of hyperandrogenism in adolescents.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

A small group of slow-growing cells causes basal cell carcinoma to return after treatment.

Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

ZD1839 can cause skin issues like acne and hair changes.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.

Vitisin A reduces triglycerides better than Cyanidin-3-O-glucoside.

Hair follicle samples effectively show how well the drug MK-0752 targets and engages with the Notch pathway.